Intuitive Surgical Stock Plummets Amid Concerns Over Competition and Valuation
Intuitive Surgical (NASDAQ:ISRG) has experienced a significant decline in its stock price this year, down around 30% as of August 2026. This would mark the worst performance since the financial crisis of 2008 if it continues. Despite strong second-quarter results with double-digit revenue and procedure growth, investors were unimpressed by management's full-year guidance for da Vinci system procedures to grow between 13.5% and 15.5%. The muted outlook has raised concerns about the company’s long-term prospects. The stock is also under pressure due to its high valuation compared to broader market averages, trading at around 45 times trailing earnings and 36 on a forward basis. Increased competition from new entrants like Johnson & Johnson's Ottava system and Medtronic's Hugo platform has further fueled investor anxiety about Intuitive’s ability to maintain dominance in the robotic surgery space. Despite these challenges, long-term growth opportunities remain intact for Intuitive Surgical due to its leadership position in a rapidly evolving healthcare sector. However, investors may need patience as the company navigates rising competition and adjusts expectations.
Topics: healthcare stocks Intuitive Surgical market performance robotic surgery